Related Experiment Videos
Asymptomatic cardiac ischemia pilot (ACIP)
C R Conti1, M G Bourassa, B R Chaitman
1Department of Medicine, University of Florida, College of Medicine, Gainesville, USA.
Insights
This pilot study shows that medical or revascularization strategies can manage asymptomatic cardiac ischemia in coronary artery disease (CAD) patients. Revascularization effectively reduced ischemia, but long-term costs and outcomes require further large-scale clinical trials.
Area of Science:
- Cardiology
- Clinical Trials
- Medical Economics
Background:
- Coronary artery disease (CAD) patients with asymptomatic cardiac ischemia present complex management challenges.
- The economic implications of treating asymptomatic ischemia are substantial, with potential long-term cost advantages if adverse events are reduced.
Purpose of the Study:
- To assess the feasibility of randomizing patients with CAD and asymptomatic cardiac ischemia to medical or revascularization strategies.
- To evaluate the effectiveness of medical therapy in suppressing asymptomatic cardiac ischemia.
- To compare the efficacy of different treatment strategies in reducing cardiac ischemia.
Main Methods:
- A pilot study involving a complex randomization protocol for patients with CAD and asymptomatic cardiac ischemia.
- Titration of low to moderate doses of medication over 12 weeks to suppress ischemia.
- Comparison of medical therapy versus revascularization strategies.
Main Results:
- Successful randomization of patients to medical or revascularization groups was demonstrated.
- Medication suppressed asymptomatic cardiac ischemia in 40-50% of patients within 12 weeks.
- Revascularization emerged as the most effective strategy for reducing ischemia in this pilot study.
Conclusions:
- Managing asymptomatic cardiac ischemia in CAD patients is feasible through randomized trials.
- Revascularization is highly effective in reducing ischemia, though long-term cost-effectiveness and impact on adverse events remain key questions.
- Large-scale clinical trials are necessary to determine optimal therapeutic strategies for reducing cardiac events and guiding future healthcare economic decisions.
Abstract:
This pilot study demonstrated that (1) patients with CAD and asymptomatic cardiac ischemia can be randomized to medical or revascularization strategies using a complex and demanding protocol, (2) asymptomatic cardiac ischemia can be suppressed in 40-50% of patients with clinically advanced coronary disease with relatively low to moderate doses of medication titrated over a period of 12 weeks (3). Revascularization was the most effective of the treatment strategies studied in reducing ischemia. Any type of therapy, whether it be drugs or revascularization requiring repetitive monitoring with ambulatory ECG or other methods to detect ischemia over a long period of time, will escalate the cost of quality medical care for our patients. Thus, the health care costs implications and treatment of asymptomatic ischemia are enormous. But the apparent cost advantage of treating only symptoms, that is ignoring all ischemia, could disappear if treatment of ischemia reduces the risk of adverse events. The clinical question to be addressed in the future is what is necessary to reduce the cardiac-event rates of death and myocardial infarction in this group of patients? Will more aggressive drug therapy eliminate more ischemia and will therapy directed at the elimination of all detectable ischemia improved clinical outcome better than therapy directed to control angina only? These questions can only be answered by a large clinical trial. The results of such a trial will provide the basis and rationale for safe and effective therapy for patients with coronary disease and evidence of cardiac ischemia. Whatever the answer to this important medical and scientific question is, it will have tremendous economic implications.(ABSTRACT TRUNCATED AT 250 WORDS)